The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abortion Safety and Use with Normally Prescribed Mifepristone in Canada
Open accessAbstract
BACKGROUND: In the United States, mifepristone is available for medical abortion (for use with misoprostol) only with Risk Evaluation and Mitigation Strategy (REMS) restrictions, despite an absence of evidence to support such restrictions. Mifepristone has been available in Canada with a normal prescription since November 2017. METHODS: Using population-based administrative data from Ontario, Canada, we examined abortion use, safety, and effectiveness using an interrupted time-series analysis comparing trends in incidence before mifepristone was available (January 2012 through December 2016) with trends after its availability without restrictions (November 7, 2017, through March 15, 2020). RESULTS: A total of 195,183 abortions were performed before mifepristone was available and 84,032 after its availability without restrictions. After the availability of mifepristone with a normal prescription, the abortion rate continued to decline, although more slowly than was expected on the basis of trends before mifepristone had been available (adjusted risk difference in time-series analysis, 1.2 per 1000 female residents between 15 and 49 years of age; 95% confidence interval [CI], 1.1 to 1.4), whereas the percentage of abortions provided as medical procedures increased from 2.2% to 31.4% (adjusted risk difference, 28.8 percentage points; 95% CI, 28.0 to 29.7). There were no material changes between the period before mifepristone was available and the nonrestricted period in the incidence of severe adverse events (0.03% vs. 0.04%; adjusted risk difference, 0.01 percentage points; 95% CI, -0.06 to 0.03), complications (0.74% vs. 0.69%; adjusted risk difference, 0.06 percentage points; 95% CI, -0.07 to 0.18), or ectopic pregnancy detected after abortion (0.15% vs. 0.22%; adjusted risk difference, -0.03 percentage points; 95% CI, -0.19 to 0.09). There was a small increase in ongoing intrauterine pregnancy continuing to delivery (adjusted risk difference, 0.08 percentage points; 95% CI, 0.04 to 0.10). CONCLUSIONS: After mifepristone became available as a normal prescription, the abortion rate remained relatively stable, the proportion of abortions provided by medication increased rapidly, and adverse events and complications remained stable, as compared with the period when mifepristone was unavailable. (Funded by the Canadian Institutes of Health Research and the Women's Health Research Institute.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Segmented regression analysis of interrupted time series studies in medication use research
Wagner, A. K., Soumerai, S. B., Zhang, F., & Ross-Degnan, D. (2002) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2002.00430.x · Cited by 3,279
Interrupted time series regression for the evaluation of public health interventions: a tutorial
Lopez Bernal, J., Cummins, S., & Gasparrini, A. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyw098 · Cited by 3,049
Haukoos, J. S., & Lewis, R. J. (2005) · Academic Emergency Medicine · doi:10.1111/j.1553-2712.2005.tb01958.x · Cited by 540
A systematic review to calculate background miscarriage rates using life table analysis
Ammon Avalos, L., Galindo, C., & Li, D. (2012) · Birth Defects Research Part A: Clinical and Molecular Teratology · doi:10.1002/bdra.23014 · Cited by 329
Medical methods for first trimester abortion
Kulier, R., Kapp, N., Gülmezoglu, A. M., Hofmeyr, G. J., Cheng, L., & Campana, A. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002855.pub4 · Cited by 284
Time Series Analysis Using Autoregressive Integrated Moving Average (ARIMA) Models
Nelson, B. K. (1998) · Academic Emergency Medicine · doi:10.1111/j.1553-2712.1998.tb02493.x · Cited by 262
Aiken, A., Lohr, P., Lord, J., Ghosh, N., & Starling, J. (2021) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.16668 · Cited by 256
Hategeka, C., Ruton, H., Karamouzian, M., Lynd, L. D., & Law, M. R. (2020) · BMJ Global Health · doi:10.1136/bmjgh-2020-003567 · Cited by 237
Self-citationA United Nations High Commissioner for Human Rights
Clark, R. S. (1972) · Springer eBooks · doi:10.1007/978-94-011-8800-5 · Cited by 209
Medication Abortion Up to 70 Days of Gestation
Society of Family Planning (2020) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000004082 · Cited by 158
Research works printed but not linked: 1
- 10.1197/j.aem.2004.11.018 · doi:10.1197/j.aem.2004.11.018 · Paper page
Cited by
Baraitser, P., Free, C., Norman, W. V., Lewandowska, M., Meiksin, R., Palmer, M. J., Scott, R. H., French, R., Wellings, K., Ivory, A., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-066650 · Cited by 41
Self-citationCarson, A., Stirling-Cameron, E., Paynter, M. J., Norman, W. V., Munro, S. B., & Martin‐Misener, R. (2022) · Journal of Advanced Nursing · doi:10.1111/jan.15487 · Cited by 24
Self-citationTelemedicine for First-Trimester Medical Abortion in Canada: Results of a 2019 Survey
Renner, R., Ennis, M., Kyeremeh, A., Norman, W. V., Dunn, S., Pymar, H. C., & Guilbert, É. (2022) · Telemedicine Journal and e-Health · doi:10.1089/tmj.2022.0245 · Cited by 18
Self-citationExperience of stigma and harassment among respondents to the 2019 Canadian abortion provider survey
Ennis, M., Renner, R., Olure, B., Norman, W. V., Begun, S., Martin, L. A., Harris, L. H., Kean, L., Seewald, M., & Munro, S. B. (2023) · Contraception · doi:10.1016/j.contraception.2023.110083 · Cited by 18
Self-citationAbortion services and providers in Canada in 2019: results of a national survey
Renner, R. M., Ennis, M., Contandriopoulos, D., Guilbert, E., Dunn, S., Kaczorowski, J., Darling, E. K., Albert, A., Styffe, C., & Norman, W. V. (2022) · CMAJ Open · doi:10.9778/cmajo.20210232 · Cited by 16
“Other evidence describing growth in the abortion work-force is emerging; 22,24,38–42 this growth appears to be associated with the 2017 introduction of mifepristone in Canada and the subsequent removal of restrictive regulations.”
Self-citationMedani, I. E., Hakami, A., Chourasia, U. H., Rahamtalla, B. M., Adawi, N. M., Fadailu, M. E., Salih, A., Abdelmola, A. O., Nasralla, K., Dawelbait, A. M., et al. (2025) · Healthcare · doi:10.3390/healthcare13162036 · Cited by 15
Carson, A., Stirling-Cameron, E., Paynter, M. J., Munro, S. B., Norman, W. V., Kilpatrick, K., Begun, S., & Martin‐Misener, R. (2023) · PLoS ONE · doi:10.1371/journal.pone.0280757 · Cited by 15
Self-citationMoulton, J. E., Arefadib, N., Botfield, J. R., Freilich, K., Tomnay, J. E., Bateson, D. J., Black, K. I., Norman, W. V., & Mazza, D. (2024) · Journal of Advanced Nursing · doi:10.1111/jan.16299 · Cited by 15
Self-citationMiscarriage after SARS‐CoV‐2 vaccination: A population‐based cohort study
Vélez, M. P., Fell, D. B., Shellenberger, J. P., Kwong, J. C., & Ray, J. G. (2023) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.17721 · Cited by 14
Short-Term Adverse Outcomes After Mifepristone–Misoprostol Versus Procedural Induced Abortion
Liu, N., & Ray, J. G. (2023) · Annals of Internal Medicine · doi:10.7326/m22-2568 · Cited by 14
Dispensing mifepristone for medical abortion in Canada: Pharmacists’ experiences of the first year
Zusman, E. Z., Munro, S. B., Norman, W. V., & Soon, J. A. (2023) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.1177/17151635231176270 · Cited by 14
Self-citationEnnis, M., Renner, R., Guilbert, E., Norman, W. V., Pymar, H., Kean, L., Carson, A., Martin-Misener, R., & Dunn, S. (2022) · Contraception · doi:10.1016/j.contraception.2022.03.020 · Cited by 13
Self-citationCourt Intrusion Into Science and Medicine—The Mifepristone Decisions
Aaron, D., Brown, T. R., & Sinha, M. S. (2023) · JAMA · doi:10.1001/jama.2023.7790 · Cited by 13
Mazza, D. (2023) · The Medical Journal of Australia · doi:10.5694/mja2.51979 · Cited by 10
Distance between institutions of incarceration and procedural abortion facilities in Canada
Paynter, M. J., & Heggie, C. (2023) · Contraception · doi:10.1016/j.contraception.2023.110079 · Cited by 10
Kaller, S., Ma, M., Gurazada, T., Baba, C. F., Rafie, S., Raine‐Bennett, T. R., Averbach, S., Chen, M. J., Berry‐Bibee, E., Meckstroth, K., et al. (2022) · Women s Health Issues · doi:10.1016/j.whi.2022.06.007 · Cited by 9
Approved but Unavailable: A Mystery-Caller Survey of Mifepristone Access in a Large Ontario City
Guarna, G., Kotait, M., Blair, R., Vu, N. M., Yakoub, D., Davis, R., & Costescu, D. (2023) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/j.jogc.2023.06.009 · Cited by 8
A global scoping review of the circumstances of care seeking for abortion later in pregnancy
Jacobson, L. E., Darney, B. G., Johnston, H. B., & Ganatra, B. (2024) · PLOS Global Public Health · doi:10.1371/journal.pgph.0003965 · Cited by 7
Blood Transfusions for Pregnancy Loss in Texas Before and After Abortion Bans, 2017‒2023
Nagle, A., Samari, G., Thaxton, L. D., & Gemmill, A. (2025) · American Journal of Public Health · doi:10.2105/ajph.2025.308224 · Cited by 7
Neill, S. N., Mokashi, M., Goldberg, A. B., Fortin, J. M., & Janiak, E. (2023) · Perspectives on Sexual and Reproductive Health · doi:10.1363/psrh.12237 · Cited by 7
Brennand, E. A., Huang, B., Scime, N. V., Paw, J., & Nelson, E. L. (2025) · The Lancet Public Health · doi:10.1016/s2468-2667(25)00010-6 · Cited by 9
Pharmacists’ experiences dispensing misoprostol and readiness to dispense mifepristone
Ferketa, M., Moore, A. L., Klein-Barton, J., Stulberg, D. B., & Hasselbacher, L. A. (2023) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2023.10.030 · Cited by 7
M1 Macrophages Are a Source of IL-1α: A Driver of Progesterone Metabolism and Myometrial Contraction
Nadeem, L., Librach, M., Boros-Rausch, A., Matthews, B. J., Cabeza, E. A., Shynlova, O. P., & Lye, S. J. (2025) · Cells · doi:10.3390/cells14211692 · Cited by 6
Haas, M. R., Church, J., Street, D. J., Bateson, D. J., & Mazza, D. (2022) · Australian Journal of Primary Health · doi:10.1071/py22130 · Cited by 6
Janiak, E., Belizaire, C., Liu, J., & Fulcher, I. (2022) · Contraception · doi:10.1016/j.contraception.2022.04.003 · Cited by 5
Efficacy and safety of medical termination of pregnancy in a regional primary care setting
Sara Xiao‐Li, L. A. I., & Amanda, C. O. H. N. (2023) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/ajo.13738 · Cited by 5
Personhood Begins at Birth: The Rational Foundation for Abortion Policy in a Secular State
Wall, L. L., & Brown, D. (2024) · Journal of Bioethical Inquiry · doi:10.1007/s11673-024-10352-0 · Cited by 5
Guilbert, É., & Bois, G. (2022) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/j.jogc.2022.11.013 · Cited by 5
Advancing Reproductive Health through Policy-Engaged Research in Abortion Care
Munro, S. B., Dunn, S., Guilbert, É., & Norman, W. V. (2022) · Seminars in Reproductive Medicine · doi:10.1055/s-0042-1760213 · Cited by 5
Self-citationRenner, R., Ennis, M., Kean, L., Brooks, M., Dineley, B., Pymar, H., Norman, W. V., & Guilbert, E. (2023) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/j.jogc.2023.08.001 · Cited by 4
Self-citationBashevkin, S. B. (2023) · Canadian Journal of Political Science · doi:10.1017/s0008423923000227 · Cited by 4
Abortion and Contraception Policy in Prisons in Canada
Paynter, M. J., & Heggie, C. (2024) · The Prison Journal · doi:10.1177/00328855241292790 · Cited by 4
The role of doulas in abortion care in Canada: A qualitative study
Paynter, M. J., Heggie, C., McLeod, A., Castonguay, M., Fuller, M., & Norman, W. V. (2025) · PLoS ONE · doi:10.1371/journal.pone.0313918 · Cited by 4
Self-citationEvidence Supports Removing Restrictions on Mifepristone
Grossman, D., & Chung, E. (2025) · JAMA · doi:10.1001/jama.2025.8138 · Cited by 4
Discovery of an Ectopic Pregnancy after Attempted Self-Managed Abortion
Beshar, I., Liu, S. M., Shaw, K. A., & Henkel, A. (2023) · New England Journal of Medicine · doi:10.1056/nejmc2214213 · Cited by 4
Trends in Abortion Rates in Ontario, Canada
Schummers, L., Dunn, S., Cheng, L., & Norman, W. V. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.4516 · Cited by 3
Self-citationHome use of mifepristone for medical abortion: a systematic review
Gemzell‐Danielsson, K., Lindh, I., Brynhildsen, J., Christensson, A., Moberg, K., Wernersson, E., & Johansson, S. (2024) · BMJ Sexual & Reproductive Health · doi:10.1136/bmjsrh-2024-202302 · Cited by 3
Witt, L. B., Wolff, S. F., Shih, G., & French, V. A. (2023) · Teaching and Learning in Medicine · doi:10.1080/10401334.2022.2163399 · Cited by 3
Agostini, A., Pauly, V., Orléans, V., Brousse, Y., Romain, F., Tran, B. X., Nguyen, T. T., Smith, L., Yon, D. K., Auquier, P., et al. (2024) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2024.07.002 · Cited by 2
Paynter, M. J. (2025) · The Lancet Public Health · doi:10.1016/s2468-2667(25)00041-6 · Cited by 2
Brennand, E. A., Scime, N. V., Huang, B., Randhawa, A., Kim-Fine, S., Aziza, O., Paw, J., & Nelson, E. L. (2025) · Contraception · doi:10.1016/j.contraception.2025.110945 · Cited by 2
Barrow, A., Cohen, C., Serpico, J. J., Goodman, M., Grossman, D., Raifman, S., & Upadhyay, U. D. (2024) · Perspectives on Sexual and Reproductive Health · doi:10.1111/psrh.12281 · Cited by 1
Jacobson, L. E., Saavedra‐Avendaño, B., Schiavon, R., & Darney, B. G. (2025) · BMC Public Health · doi:10.1186/s12889-024-21182-5 · Cited by 1
Mate Whenua—follow-up after early medical abortion: study protocol for a randomized controlled trial
WISE, M. R., MacDonald, E. J., Knowles, A., Talbot, S., Shankar, S. I. A., Gibbons, B. M., LAWTON, B. A., Parag, V., Baker, A. O., & Amjad, S. (2025) · Trials · doi:10.1186/s13063-025-09016-0 · Cited by 1
Mifepristone Access Through Community Pharmacies When Regulated as a Routine Prescription Medication
Nethery, E., Xu, C., Chan, C. S. Y., Helmer‐Smith, M., Stucchi, A., Mooney, D., Zusman, E. Z., Dunn, S., Pammett, R. T., Norman, W. V., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.42096 · Cited by 1
Self-citationMunro, S., Ennis, M., Wahl, K., & Williams, A. (2025) · BMC Family Practice · doi:10.1186/s12875-025-03043-1 · Cited by 1
Canada leads international movement to enhance accessible, safe abortion services
Paynter, M. J., & Norman, W. V. (2025) · Canadian Family Physician · doi:10.46747/cfp.711112693 · Cited by 1
Self-citationWellings, K., French, R., Aronsson, A., Baraitser, P., Cameron, S., Free, C., Keogh, L. A., Lewandowska, M., Lohr, P. A., Meiksin, R., et al. (2025) · Health and Social Care Delivery Research · doi:10.3310/asgw2227 · Cited by 1
Self-citationEckstein, S. M., von Felten, S., Perotto, L., Brun, R., & Vorburger, D. (2023) · Scientific Reports · doi:10.1038/s41598-023-34101-2 · Cited by 1
US drugs agency approves abortion pill by mail but many states limit access
Tanne, J. H. (2021) · BMJ · doi:10.1136/bmj.n3120 · Cited by 1
Health Reform Observer - Observatoire des Réformes de Santé
(2024) · Health Reform Observer - Observatoire des Réformes de Santé · doi:10.13162/issn.2291-6369 · Cited by 1
Rowlands, S., & Harrison‐Woolrych, M. (2023) · BMJ Sexual & Reproductive Health · doi:10.1136/bmjsrh-2023-201949 · Cited by 1
The SOGC Supports High-Quality, Accessible Abortion Care
Norman, W. V., Wilson, R. D., & Francoeur, D. (2022) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/j.jogc.2022.08.001
Self-citationLa SOGC plaide en faveur de l’accès aux soins d’avortement de haute qualité
Norman, W. V., Wilson, R. D., & Francoeur, D. (2022) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/j.jogc.2022.08.002
Self-citationMazer-Amirshahi, M. E., Stolbach, A. I., & Ye, P. P. (2023) · Journal of Medical Toxicology · doi:10.1007/s13181-023-00960-4
Restrictions on pharmacist dispensing of mifepristone remain a hard pill to swallow
Boyden, K., Hatton, R. C., Lynch, C., & Brushwood, D. B. (2024) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.2034
Regulation of Controlled Substances and Reproductive Health
Tasset, J., Scarsi, K. K., & Edelman, A. B. (2025) · JAMA · doi:10.1001/jama.2025.0384
Abortion Ratios After First-trimester Exposure to Teratogenic Medication in People with Disabilities
Camden, A., Sharpe, I., Lu, H., & Brown, H. K. (2025) · Epidemiology · doi:10.1097/ede.0000000000001851
Nádas, M., Becker, O., Mallow, M., & Rand, S. E. (2025) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2024.12.014
Reproductive Health Policy in Canada
Nelson, E. L. (2025) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780197766859.013.0031
Medical Necessity as an Ethical Imperative for Equitable Access to Abortion Services in Canada
Dhamanaskar, R., Benjamin, K. A., Keer, K., & Chauhan, N. (2025) · Canadian Journal of Bioethics · doi:10.7202/1118905ar
In reproductive health policy and access, Canada is not the 51st US state
Schummers, L., & Norman, W. V. (2025) · BMJ Sexual & Reproductive Health · doi:10.1136/bmjsrh-2025-202912
Self-citationThe Sociodemographic Benefits of Extending MS ‐ 2Step to 70 Days in Australia
Slade, L. J., Louise, J., D’Onise, K., & Dodd, J. M. (2025) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/ajo.70077
Paynter, M. J., & Norman, W. V. (2025) · Canadian Family Physician · doi:10.46747/cfp.711112e258
Self-citationAssessing the Impact of Approval of Mifegymiso on Abortion Access and Care in Canada
Poppel, A., & Mauthe, T. (2025) · Health Reform Observer - Observatoire des Réformes de Santé · doi:10.13162/hro-ors.v12i3.6693
Hautala, R. (2024) · MacSphere (McMaster University) · doi:10.71548/21440
Richards, N. K. (2024) · UWSpace (University of Waterloo)
Battiston, S., Thewani, N., Gear, G., & Stanton, T. (2025) · BMJ Case Reports · doi:10.1136/bcr-2025-268796
Jain, N., Fahner, A.-F., Kumah, J., Chodnekar, S. Y., Ussher, F. A., Mohan, S., Kaushik, I., Akbari, A. R., Lica, M., Owusu, B. O., et al. (2026) · Women s Health · doi:10.1177/17455057251410331
Mehta, P., Norman, W. V., & Abdulai, A. (2026) · BMJ Sexual & Reproductive Health · doi:10.1136/bmjsrh-2026-203242
Self-citationDuong, M.-C., Czerniak, E., Mehta, A., Chiu, R., Norman, W. V., & Abdulai, A. (2026) · BMJ Sexual & Reproductive Health · doi:10.1136/bmjsrh-2026-203275
Self-citationAstatke, R. H. (2026) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Woskie, L., Strasser, J. H., Griffin, R., Luo, Q., Rodriguez, M. I., & Upadhyay, U. D. (2026) · medRxiv · doi:10.64898/2026.10.02.26364611
Regulatory Policy Changes and Mifepristone Access Through Pharmacies in Australia
Edvardsson, K., Schummers, L., Moulton, J. E., Li, X., Cheng, L., Mazza, D., Goldstone, P., & Grossman, D. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.37766
Self-citationBrooks, M. L., Richardson, H., Abdulai, A., Janssen, P., Munro, S. B., & Dol, J. (2026) · BMJ Sexual & Reproductive Health · doi:10.1136/bmjsrh-2026-203281
Mifepristone Patient Agreement Form and Medication Abortion Knowledge
Biggs, M. A., Ehrenreich, K., Kaller, S., Ralph, L. J., & Grossman, D. (2026) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2026.5197
Mate Whenua—Follow‐Up After Early Medical Abortion in New Zealand: A Randomised Controlled Trial
WISE, M. R., Knowles, A., Talbot, S., Parag, V., LAWTON, B. A., Edmonds, M., Gibbons, B. M., Amjad, S., & MacDonald, E. J. (2026) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.70346
Metadata
- Authors
- Schummers, L., Darling, E. K., Dunn, S., McGrail, K., Gayowsky, A., Law, M. R., Laba, T.-L., Kaczorowski, J., & Norman, W. V.
- Affiliations
- University of British Columbia (CA)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-01-06
- Volume
- 386
- Issue
- 1
- Pages
- 57-67
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4200143757
- Cited by
- 71
- References
- 31
- Citations by year
- 2026: 8 · 2025: 22 · 2024: 9 · 2023: 19 · 2022: 12
- FWCI
- 8.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Funders
- Institute of Health Services and Policy Research (Canada Chair in Prevention and Control of Hyperten, Early Career Researcher: ECI-167971, Health System Impact Fellowship 2018 Schummers, Patient-Oriented Research Award – Transition to, Project Grant PJT-168964 2020-24, Public Health Research Chair: CPP-329455-107837 20)
- British Columbia Ministry of Health (18183)
- Michael Smith Foundation for Health Research (17934, 2012-5139 HSR)
- Canada Research Chairs (Canada Research Chair in Access to Medicines)
- National Health and Medical Research Council (Early Career Fellowship (APP1110230))
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- mifepristone, abortion pills, abortion safety, risk evaluation and mitigation strategy, drug regulation, prescribing restrictions, misoprostol, Canada
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.